Literature DB >> 6167493

Biliary lipids, faecal steroids, and liver function in patients with chronic active hepatitis and primary biliary cirrhosis: significance of hepatic orcein-stained complexes.

Y A Kesäniemi, T A Miettinen, M P Salaspuro.   

Abstract

Biliary lipids, faecal steroids, and serum bile acids were studied in patients with chronic active hepatitis and primary biliary cirrhosis. The results were correlated with excretory and parenchymal liver function tests and with the presence or absence of orcein-positive copper-protein complexes in histological liver specimens. In general, faecal bile acids, but not neutral and total sterols, correlated negatively with the percentage of biliary cholic acid, serum cholesterol, and serum bile acids and positively with the percentage of biliary deoxycholic acid. In orcein-positive subjects-indicative of long-standing cholestasis-the bile was undersaturated with cholesterol, biliary deoxycholic acid was subnormal, cholic acid correspondingly increased, and serum cholesterol and bile acids were raised. Only patients with marked impairment of both excretory and parenchymal liver functions had a decreased output of neutral sterols, bile acids, and total steroids, and, thus, low bile acid and cholesterol synthesis. The findings indicate that mild disturbances in parenchymal liver function infrequently cause major changes in cholesterol metabolism, while abnormalities in secretory liver function-in orcein-positive subjects especially-are frequently associated with proportionate changes in parameters of cholesterol metabolism.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6167493      PMCID: PMC1419325          DOI: 10.1136/gut.22.7.579

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  37 in total

1.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

2.  QUANTITATIVE ISOLATION AND GAS--LIQUID CHROMATOGRAPHIC ANALYSIS OF TOTAL FECAL BILE ACIDS.

Authors:  S M GRUNDY; E H AHRENS; T A MIETTINEN
Journal:  J Lipid Res       Date:  1965-07       Impact factor: 5.922

3.  A simplified method for the determination of chromic oxide (Cr2 O3) when used as an index substance.

Authors:  D W BOLIN; R P KING; E W KLOSTERMAN
Journal:  Science       Date:  1952-12-05       Impact factor: 47.728

Review 4.  Nonsuppurative destructive chronic cholangitis and chronic hepatitis.

Authors:  H Popper; F Schaffner
Journal:  Prog Liver Dis       Date:  1970

5.  Demonstration of an intracellular copper-binding protein by orcein staining in long-standing cholestatic liver diseases.

Authors:  M Salaspuro; P Sipponen
Journal:  Gut       Date:  1976-10       Impact factor: 23.059

6.  The metabolism of intravenously injected isotopic cholic acid in Laennec's cirrhosis.

Authors:  M Blum; N Spritz
Journal:  J Clin Invest       Date:  1966-02       Impact factor: 14.808

7.  Usefulness of chromic oxide as an internal standard for balance studies in formula-fed patients and for assessment of colonic function.

Authors:  J Davignon; W J Simmonds; E H Ahrens
Journal:  J Clin Invest       Date:  1968-01       Impact factor: 14.808

8.  Bile salt secretion in cirrhosis of the liver.

Authors:  L A Turnberg; G Grahame
Journal:  Gut       Date:  1970-02       Impact factor: 23.059

9.  Biliary transport and hepatic storage of sulfobromophthalein sodium in the unanesthetized dog, in normal man, and in patients with hepatic disease.

Authors:  H O WHEELER; J I MELTZER; S E BRADLEY
Journal:  J Clin Invest       Date:  1960-07       Impact factor: 14.808

10.  Lipid absorption, bile acids, and cholesterol metabolism in patients with chronic liver disease.

Authors:  T A Miettinen
Journal:  Gut       Date:  1972-09       Impact factor: 23.059

View more
  1 in total

1.  Biliary lipid secretion in chronic cholestatic liver disease.

Authors:  Y A Kesäniemi; M P Salaspuro; M Vuoristo; T A Miettinen
Journal:  Gut       Date:  1982-11       Impact factor: 23.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.